Axsome Therapeutics's results for Q3 2026 (ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-11-02. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $260 million (+51.9% vs a year earlier) |
| Diluted EPS (GAAP) | $-0.25 |
| Full-year guidance | No outlook given |
Guidance
No revenue or EPS outlook; company says current cash is sufficient to fund anticipated operations into cash flow positivity.
Why this label: 'Financial Guidance' is only a cash-runway statement; no revenue/EPS figures.
From the release
Revenue: "Total net product revenue was $259.7 million for the third quarter of 2026, representing 52% year-over-year growth. Total net product revenue for the comparable period in 2025 was $171.0 million."
Earnings per share: "Net loss for the third quarter of 2026 was $12.9 million, or $(0.25) per share, compared to a net loss of $47.2 million, or $(0.94) per share"
Key fact: Q3 total revenue rose 52% to $259.7 million; Auvelity sales up 53%.
Source
Axsome Therapeutics earnings release (SEC filing), accession 0001193125-26-442628, filed 2026-11-02.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.